Michael D. Triplett, PhD

Michael D. Triplett, PhD, is the co-chairman of the board of directors at Clarametyx Biosciences, Inc. Michael was previously the president and chief executive officer of Myonexus Therapeutics, Inc., which was acquired by Sarepta Therapeutics, Inc. in April 2019. Prior to that, they were the director of strategic marketing for health and life sciences at Battelle from December 2007 to October 2012. Michael has also held positions at N8 Medical, Inc., Carmen Partners, LLC, and Ohio Innovation Fund.

Michael D. Triplett, PhD has a Ph.D. in Chemical Engineering and a B.S. in Chemical Engineering from The Ohio State University.